The Carlyle Group Inc. (NASDAQ: CG) — The Cheapest Big-Cap Alternative Manager, and Partly for Good Reason

Independent fundamental research Report date: 2026-06-13 · Price: $45.75 · Market cap ~$16.5B · 52-wk range $41.54–$69.85

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analysis that follows takes no position and carries no price target; this opening block is the single place a view is expressed.

Verdict: HOLD — accumulate on weakness below ~$42. A genuine value setup wearing a real quality discount. Medium conviction. Directional zone: At ~$45.75 the stock trades at roughly 10–11× trailing distributable earnings (DE ≈$4.20/share) and ~13× fee-related earnings — the cheapest of the big-four alternative managers (Blackstone ~21×, KKR ~20×, Apollo ~16× on comparable trailing earnings). A fair range for a sub-scale-margin, carry-heavier, slower-growing-flagship franchise that is nonetheless de-risking its earnings is ~11–14× DE, i.e. ~$46–$59. The stock sits at the floor of that band. I would accumulate below ~$42 (near the 52-week low and ~10× DE), hold in the mid-$40s, and trim only into a re-rate through the high-$50s absent proof the 2028 plan is landing.

Carlyle is the value name in a quality sector. The bull and bear are unusually symmetric. The bear: it is cheap for reasons — the lowest fee-related-earnings margin in its peer set (~47% vs. 57–69%), a flagship private-equity engine (GPE) whose fee-earning AUM and FRE have fallen three years running, the lowest genuine perpetual-capital mix (~$35B ex the low-fee Fortitude advisory book, vs. 40–90% perpetual at peers), a flagship buyout fund (CP VIII) whose size management pointedly will not disclose, and — the tell that matters most to me — zero insider open-market buying as the stock fell 22% in 2026 while founders (Rubenstein) sold discretionarily, in stark contrast to KKR’s co-CEOs putting ~$51M of their own money in during the same drawdown. CEO Harvey Schwartz’s upper incentive tranches ($58–72 hurdles) are now well underwater, which is honest alignment but also a scoreboard reading “behind.” The bull: the earnings mix is genuinely improving — FRE is now 73% of DE (up from ~60%), Global Credit + AlpInvest are ~55% of firm FRE (up from ~25% five years ago) and compounding ~20%+, the dividend (3.1% yield) is covered at <50% of DE, there’s a fresh $2B buyback, and the franchise is being bought at a price that implies the credible-if-back-loaded 2028 plan ($1.9B FRE, $6+ DEPS) simply fails. Framing: deep-value / show-me turnaround, not quality-compounder. You are paid to wait, and the downside is cushioned by the discount and the yield — but this is the manager you buy because it’s cheap, not because it’s best.

Conviction: Medium. Flips bullish if H2-2026 fundraising (the “super-cycle”: CP IX launch, next AlpInvest secondaries vintage, opportunistic credit) lands and FRE growth visibly re-accelerates toward the $1.9B/2028 path and an insider finally buys. Flips bearish if CP IX raises materially below CP VII (~$14.8B), FRE margin stalls in the mid-40s, or the CTAC retail-credit redemptions that began in Q1-2026 broaden into the institutional book.

One-liner: Best price on the worst house on a very good street — and the discount is wide enough to matter.

1. Executive Summary

The Carlyle Group is a $477 billion global alternative asset manager organized in three segments — Global Private Equity (GPE), Global Credit (GC), and Global Investment Solutions (“Carlyle AlpInvest,” GIS). It is one of a handful of scaled incumbents in a structurally attractive, oligopolistic industry, but within that elite group it is the laggard on nearly every quality metric that the market rewards: fee-related-earnings margin, perpetual-capital mix, and flagship-fund momentum. It is also, not coincidentally, the cheapest — trading at roughly 10–11× trailing distributable earnings versus 16–21× for Blackstone, KKR, and Apollo.

The investment debate reduces to a single question: is Carlyle’s ~40% valuation discount to its best-in-class peers a permanent quality deficit, or a mispricing that a credible turnaround is beginning to close? The evidence cuts both ways and is unusually balanced.

The case that the discount is deserved (Facts). Carlyle’s FRE margin is ~47%, against 57% at Blackstone and Apollo and 69% at KKR — a structural profitability gap, not a one-year blip. Its flagship Global Private Equity engine has seen fee-earning AUM stagnate (~$101B in 2025 vs. ~$107B in 2023) and segment FRE decline for three consecutive years. “Perpetual capital” of $115B is ~70% the low-fee Fortitude insurance advisory book; genuine retail/evergreen perpetual capital is only ~$35B. Management will not disclose the size of its in-market flagship buyout fund (CP VIII), and is using a $5B structured anchor to cornerstone the next fund (CP IX) — a plausible signal of softer traditional-LP demand. And no insider has bought a single open-market share during a 22% drawdown, while founders sold.

The case that it is mispriced (Facts). The earnings base is de-risking fast: FRE has compounded ~20%/year over three years while volatile carry-driven DE grew ~9%, so fee-related earnings are now 73% of DE (up from ~60%). Global Credit and AlpInvest together generate ~55% of firm FRE (up from ~25% five years ago) and are growing ~20%+. The balance sheet is asset-light and clean (~$2.7B debt, >$3.1B cash, no insurance liabilities). The dividend yields 3.1% and is covered at <50% of DE; there’s a fresh $2B repurchase authorization. Management has put a hard 2028 target on the table — $200B of inflows, $1.9B FRE, $6+ DE/share — and at today’s price the market is paying ~7.6× those 2028 earnings, i.e. underwriting that the plan fails.

Verdict of the body (no recommendation): Carlyle is a structurally good business inside a structurally good industry, run by a credible but not-yet-proven turnaround team, priced as though the turnaround will not happen. The quality gap to peers is real and should not be wished away; the discount that prices it may nonetheless be too wide. The reader should weigh the “What Must Be True” falsification tests below — flagship fundraising, FRE re-acceleration, and FRE-margin progression — as the live determinants of which case is correct.

2. Business Overview

Carlyle, founded in 1987 and headquartered in Washington, D.C., is one of the world’s largest alternative asset managers, with $476.9 billion of assets under management (AUM) and $336.8 billion of fee-earning AUM (FEAUM) at year-end 2025 (Q1-2026: $475.4B AUM / $333.4B FEAUM). It earns money the way all alternative managers do: it raises long-dated, locked-up capital from institutional and (increasingly) wealthy individual investors, charges management fees on that capital (recurring, predictable), and earns performance fees / carried interest on investment gains above a hurdle (lumpy, market-dependent). The first stream, plus fee-related performance revenues, drives Fee Related Earnings (FRE); the combination of FRE and realized net carry drives Distributable Earnings (DE) — the cash-economic profit the market actually values. GAAP net income, distorted by mark-to-market on unrealized carry and fund consolidation, is close to meaningless here (diluted GAAP EPS swung from $8.20 in 2021 to −$1.68 in 2023 to $2.18 in 2025); the body uses the non-GAAP operating metrics throughout, reconciled to the 10-K.

Three segments (FY2025):

• Global Private Equity — corporate buyouts (flagship Carlyle Partners US funds, Europe, Asia), real estate (Carlyle Realty Partners), infrastructure, and energy. The highest fee rate (~1.17%) and historically the firm’s identity, but the slowest-growing segment: GPE FEAUM has gone backwards since 2023 and segment FRE has fallen three straight years ($564.8M → $598.7M → $560.9M, with 2024’s bump reversed in 2025). This is the heart of the bear case.
• Global Credit — the growth engine. CLOs (Carlyle is the #1 US CLO manager, ~$50B, 39 priced in 2025), direct lending (~$13B), asset-based finance (>$12B, +30% YoY), opportunistic credit (~$20B), and the insurance/Fortitude advisory book (~$80–87B). GC FRE nearly doubled in two years ($224.4M → $401.5M). Low headline fee rate (~0.36%) because the large, low-fee insurance and CLO balances dominate.
• Global Investment Solutions (Carlyle AlpInvest) — secondaries, primary fund investments, and co-investments (the former AlpInvest and Metropolitan businesses). The standout grower: FEAUM up ~45% in two years, FRE up ~4× ($70.2M → $273.8M), now ~22% of firm FRE and the highest-margin segment (~53%). Closed the largest-ever $20B secondaries fund in 2025.

Revenue quality. The strategic story is the shift from a carry-heavy, PE-centric profile toward recurring, fee-related earnings: FRE was 73% of DE in 2025 versus ~60% in 2023. Roughly 55% of firm-wide FRE now comes from Global Credit and AlpInvest, up from ~25% five years ago (management, Q3-2025 call — directionally consistent with the segment FRE table). The business is becoming more annuity-like and less dependent on the timing of fund exits, which is precisely what should narrow the multiple gap to peers if it continues.

Verdict: A genuine, scaled, three-legged alternative manager with a clear and favorable mix-shift underway — but anchored by a flagship PE franchise that has stopped growing. The composition of the business is improving faster than the whole.

3. Industry Dynamics

Alternative asset management is one of the more attractive structures in financial services, and the scaled incumbents — Blackstone, Apollo, KKR, Carlyle, Ares, Brookfield, Blue Owl — sit at its center.

Profit pool and structure. The industry runs on long-dated, contractually locked capital that generates high-margin, recurring management fees, topped by performance fees. Barriers to entry at scale are very high: a new entrant cannot conjure a multi-decade track record, LP relationships, or a trillion-dollar fundraising machine. The result is a consolidating, “K-shaped” industry — limited partners are concentrating commitments into fewer, larger managers, which structurally advantages the top handful. Carlyle is firmly inside that group by size, but on the tier edge relative to the $1T+ Blackstone and the faster-growing Apollo/KKR.

Three secular tailwinds (Facts / Interpretation):

1. Rising institutional allocations to alternatives — pensions, endowments, and sovereign funds continue to raise target allocations to private markets.
2. Retail / wealth and 401(k) penetration — alternatives are a low-single-digit share of individual portfolios; a 2025 U.S. executive order easing private assets into defined-contribution (401(k)) plans is a multi-year tailwind. Carlyle has built three wealth “flagships” (CTAC credit, AlpInvest CAPM/CAPS secondaries, a PE evergreen launching in 2026) and grown evergreen inflows ~10× under Schwartz.
3. Insurance balance-sheet migration into private credit — insurers are moving general-account assets into privately originated, investment-grade credit. This is the dominant growth vector for Apollo (Athene) and KKR (Global Atlantic), and a meaningful but asset-light lever for Carlyle (Fortitude advisory).

Capital-cycle caution (Marathon lens — Interpretation). The private-credit slice shows textbook late-cycle signatures: capital roughly tripled in five years, spreads and fees have compressed, the marketing frontier has moved from institutions to retail (a classic top signal), dry powder is at records, and Fitch’s U.S. private-credit default rate hit a record ~6.0% in April 2026. Most acutely, a June-2026 sector-wide retail redemption wave struck — Blackstone’s BCRED saw ~10% redemption requests (invoking its 5% cap), Blue Owl’s flagship interval fund was gated at ~40%, and Cliffwater/BlackRock-HPS vehicles saw double-digit requests. This de-rated the entire group (Blackstone −38%, KKR −37%, Blue Owl ~−two-thirds peak-to-trough; Apollo least affected). Carlyle’s stock fell ~22% in sympathy. The critical structural point for Carlyle: its credit book is overwhelmingly institutional/CLO/insurance, with only a modest retail-NAV slice (CTAC + BDCs). CTAC did see “elevated redemptions” in Q1-2026 that management expects to persist, but the firm is far closer to the redemption-insulated end of the spectrum (KKR) than the reflexive, retail-NAV-heavy end (Blue Owl).

Regulatory backdrop. The 401(k) order is a tailwind. Offsetting scrutiny falls mainly on the insurance-flywheel models (Bermuda/Pillar-Two global-minimum-tax exposure — Apollo took a $1.7B Bermuda DTA write-off in Q1-2026), and on conflicts/related-party concerns where GPs originate assets for affiliated insurers. Carlyle’s asset-light insurance posture largely sidesteps the insurance-tax and balance-sheet risk that weighs on Apollo/KKR — a quiet relative positive.

Verdict: structurally good industry, mid-cycle-to-late in the private-credit sub-segment. The long-term secular case for scaled alternatives is intact and favors incumbents; the near-term capital-cycle risk is concentrated in retail private credit, where Carlyle’s exposure is below-average. Net: a good industry in which Carlyle is well-positioned structurally but competitively second-tier on growth.

4. Competitive Position

Where is the moat, and what type? In Greenwald’s taxonomy, the durable advantages in this industry are (a) intangibles — track record, brand, and LP trust accumulated over decades, which create high switching costs at the institutional level; (b) economies of scale — the ability to spread a global origination, fundraising, and operating platform across an enormous fee base; and © customer captivity — locked-up, multi-year (often perpetual) capital that cannot redeem. Carlyle possesses all three, but less of each than its top-tier peers.

• Intangibles / track record: Carlyle is a 38-year-old global brand with a credible record across buyouts, credit, and solutions, and is the #1 US CLO manager. But its flagship buyout returns and fundraising momentum have lagged Blackstone’s and KKR’s in the current cycle, and the brand premium that lets the best managers raise ever-larger flagships is visibly weaker here (flat GPE FEAUM; undisclosed CP VIII; a structured anchor needed for CP IX).
• Scale economies: At $477B AUM Carlyle has real scale — but its ~47% FRE margin is the clearest evidence that it converts that scale into profit less efficiently than peers (Blackstone/Apollo ~57%, KKR ~69%). A genuine scale moat shows up as a widening margin advantage; Carlyle’s margin is rising only slowly (46% → 47%) and from a structurally lower base. This is the single most important competitive fact in the report: if the scale advantage were as strong as peers’, the margin would not be 10–22 points lower.
• Customer captivity / locked capital: Carlyle’s $115B of “perpetual capital” is ~24% of AUM — but ~$80B of it is the low-fee Fortitude advisory book; genuine retail/evergreen perpetual capital is only ~$35B. Peers run far higher genuine permanent-capital mixes (KKR ~92% perpetual-or-long-locked; Blue Owl ~85%; Blackstone ~41%). Carlyle’s capital is locked (good), but a larger share of it is in finite-life funds that must be re-raised — which is exactly why the flagship-fundraising question is existential here.

Head-to-head. Against Blackstone (scale leader, best brand, $1.3T), Apollo (credit/insurance compounding machine), and KKR (best FRE margin, balance-sheet investing, insider-aligned), Carlyle is the #4 by quality on the metrics that drive the multiple: lower margin, slower flagship growth, lower genuine perpetual mix, more carry-dependence. Where it competes well: AlpInvest is a top-tier secondaries franchise growing faster than most peers’ equivalents; the CLO platform is #1 in the US; and the asset-light model avoids the insurance-tax and credit-mark risks now dogging the insurance-heavy names.

Does the moat tie to a financial outcome? Partly. The locked capital and track record produce a recurring, high-return fee stream (FRE-related return on equity is high; the franchise earns far above its cost of capital). But the incomplete scale advantage is visible in the margin, and a moat that delivers a 47% margin where rivals earn 57–69% is a narrower moat, not the absence of one.

Verdict: a real but second-tier moat — durable advantage in absolute terms, competitively disadvantaged in relative terms. Carlyle is not a crowded-market commodity manager; it is a genuine oligopolist. But it is the weakest oligopolist in its peer set, and the financials say so.

5. Growth History and Forward Opportunities

History (Facts). Over three years AUM grew from ~$426B (2023) to ~$477B (2025), ~6%/year — respectable but trailing the faster compounders. The more important story is where the growth came from and the divergence in earnings quality:

FRE compounding at ~20% while DE grew ~9% is the de-risking thesis in one line: the recurring, fee-related base is growing much faster than the volatile carry-driven total. But the growth is entirely Credit + Solutions; the flagship PE engine went backwards:

Forward opportunities (Fact / management framing — treat as hypothesis):

• Global Credit: asset-based finance (management calls ABF “one of the greatest growth areas”), CLO leadership, and insurance (Fortitude + new reinsurance sidecars; management guides to “>$20B of new insurance AUM in the intermediate term”).
• AlpInvest / secondaries: record $6.8B Q1-2026 inflows, GP-led continuation vehicles, the largest-ever $20B secondaries fund — the clearest organic compounder in the firm.
• Wealth channel: evergreen inflows ramped from ~$300M/quarter at Schwartz’s arrival to ~$3B/quarter; three wealth flagships across credit, secondaries, and (2026) PE.
• The H2-2026 “super-cycle”: management’s stated catalyst is a cluster of flagship raises — CP IX launch, the next AlpInvest secondaries vintage, opportunistic credit — that it says will re-accelerate management fees over the next two years (“we expect to see management fees accelerate,” CFO Plouffe, Q1-2026).
• The hard 2028 target: management has explicitly guided to $200B cumulative inflows, $1.9B FRE, and $6+ DE/share by end-2028 (“we fully expect to achieve or exceed each of these goals,” Q1-2026). $1.9B FRE versus $1.236B in 2025 implies a ~15%/year FRE CAGR — an acceleration from the soft Q1-2026 (FRE −3.4% YoY), and the single most important testable claim in the report.

Verdict: high-quality growth where it is growing (Credit, Solutions, wealth), but the whole is hostage to the flagship. The mix-shift is real and valuable. The risk is that the stagnant GPE engine and a soft start to 2026 mean the 2028 FRE target requires a re-acceleration the recent run-rate does not yet show. This is high-quality growth with a credibility gap, not a smooth compounder.

6. Financial Quality

Earnings. On the metrics that matter, FY2025 produced FRE of $1,236.2M (~47% margin) and DE of $1,691.2M (~$4.20/share), with FRE now 73% of DE. Realized net performance revenues contributing to DE were $357.3M (2025) versus $366.1M (2024) — the carry contribution is steady but no longer the swing factor it once was. Q1-2026 was soft: FRE $300.0M (−3.4% YoY) and DE $327.0M (−28% YoY) — but the DE drop was almost entirely a carry-realization timing effect (realized performance revenues collapsed to $61.8M from $355.1M), not a deterioration in the fee base. This is exactly the kind of optical weakness that frightens a market already nervous about the sector and helps explain the cheap multiple.

The carry bank (forward fuel). Net accrued performance revenues attributable to Carlyle stood at $2,859.3M at YE2025, declining to $2,587.8M in Q1-2026 as realizations outpaced new accrual. Gross accrued performance allocations were $7.6B (GPE $5.0B / GC $0.7B / GIS $1.9B). Importantly, the flagship CP VII fund is only now beginning to return capital (DPI >70%, ~$17B remaining fair value) and is not yet in cash carry; CP VIII is even earlier. So a meaningful slug of future realized carry is deferred but visible — supportive of DE in 2027–2028 if exit markets cooperate.

Margins. The ~47% FRE margin is the franchise’s defining financial weakness — 10 to 22 points below peers. Management’s plan is to “grow into” higher margins via revenue scale rather than cost-cutting (wealth headcount rose ~50% in 2025), and there is no stated numeric margin target on any earnings call. Margin has improved ~300bp over three years, which is progress, but the gap to KKR’s 69% is structural and will not close quickly.

Balance sheet (a clear strength). Carlyle is asset-light and clean: ~$2.7B of debt (including $800M of 5.05% notes due 2035 issued Sept-2025), >$3.1B of cash/short-term investments, an undrawn $1.0B revolver, and no insurance liabilities on the balance sheet (it owns only ~10.5% of Fortitude, indirectly, via a fund). Net balance-sheet value is ~$5B / ~$14 per share. This contrasts favorably with the insurance-heavy peers, who carry hundreds of billions of policyholder liabilities and the attendant credit and regulatory risk. GAAP book value per share is low ($4.58) because of buybacks and non-controlling interests; tangible book is ~$18/share — but book value is not the right lens for a fee-based manager.

Quality-of-earnings flags. (1) GAAP is unusable; rely on FRE/DE, reconciled to filings. (2) The Q1-2026 DE drop is timing, not impairment — but it does pressure the trailing P/DE optics. (3) A tax-receivable agreement and non-controlling interests complicate the GAAP-to-DE bridge. (4) The “perpetual capital” headline ($115B) overstates genuine sticky retail capital (~$35B ex-Fortitude). (5) Evergreen-AUM figures cited by management ($32B vs. $19B in different quarters) use different denominators — a definitional inconsistency to treat skeptically.

Verdict: economics are sound and improving, but the scale-margin is sub-par. Cash generation is real, the balance sheet is a fortress by sector standards, and the earnings mix is de-risking. The blemish — and it is the one the market fixates on — is that Carlyle converts its scale into profit less efficiently than every large peer.

7. Capital Allocation

Returns to shareholders. Carlyle pays a fixed $1.40/share annual dividend ($0.35/quarter — note this is a fixed policy, not the old variable-payout model), costing ~$505M in 2025 and yielding ~3.1% at $45.75, covered at <50% of DE. It runs a buyback program freshly expanded to $2.0B (from a near-exhausted $1.4B authorization): $400M repurchased in 2025 (7.5M shares) and $205M in Q1-2026, with ~$1.9B remaining. Share count is roughly flat (362.3M → 357.4M, 2022→2025) as buybacks offset stock-based compensation. Management’s stated priority order is: (1) invest for growth, (2) dividend + buyback, (3) inorganic — and it repeatedly characterizes the stock as cheap to justify repurchases.

M&A. Bolt-on and distribution-oriented, not transformational: a ~$3B acquisition of MAI Capital Management (wealth/RIA distribution) and an $8B BASF coatings carve-out (a portfolio investment, not a corporate deal). No Athene/Global-Atlantic-style insurance acquisition — consistent with the deliberate asset-light strategy.

Incentive alignment (the most revealing section — Facts). CEO Harvey Schwartz’s 2023 sign-on award had a $180M grant-date fair value (2,031,602 time-RSUs + 4,730,617 performance-RSUs), granted under the Nasdaq inducement exception outside the regular plan. The PSUs vest on absolute 30-day-average stock-price hurdles of $42.74 / $51.29 / $58.12 / $64.96 / $71.80 (125%–210% of the $34.19 base), with the top two tranches additionally gated on relative TSR ≥60th percentile vs. S&P 500 Financials. The first three hurdles were hit (2024–2025); the upper $58–72 tranches are now well above the current ~$45.75 price — i.e., a large portion of the CEO’s incentive is underwater. This is genuine alignment (he is paid to get the stock to the high-$50s–low-$70s), but the scoreboard currently reads “behind.” The company-selected performance measure for incentive comp is FRE; the annual bonus is a discretionary 0–200% scorecard (Schwartz scored 200% for 2025 despite the −22% stock — a say-on-pay sore point). Say-on-pay support has run 68% (2023) → 81% (2024) → ~82% (2026) — recovered but never robust, a residue of the inducement quantum.

Founder behavior (a negative tell). Founders Rubenstein, Conway, and D’Aniello still own ~24% combined (D’Aniello 9.0%, Rubenstein 7.6%, Conway 7.5%). In the 2025–2026 drawdown, Rubenstein sold 625K shares at $56.55 (Dec-2025) and 500K at $46.68 (Mar-2026) — and the filings confirm these were discretionary, NOT 10b5-1-planned. Conway gifted 3.0M shares (charitable). No insider bought a single open-market share — the opposite of KKR, where co-CEOs and directors invested ~$51M of their own money into the same drawdown.

Verdict: disciplined, shareholder-friendly, well-aligned on paper — but the insider signal is a negative. Capital allocation is rational (covered dividend, opportunistic buyback at a cheap multiple, bolt-on M&A, FRE-linked incentives, underwater CEO tranches). The absence of any insider buying and the founders’ discretionary selling, against a peer that bought aggressively, is the most discordant note and tempers the “management believes it’s cheap” narrative they tell on calls.

8. Changes and Headwinds — Last Two Years

Management rebuild under Schwartz (Fact). Since Harvey Schwartz became CEO (Feb-2023, ex-Goldman), Carlyle has turned over most of its senior bench: a new COO (LoBue, 2024), a CFO handoff (Redett → Justin Plouffe, effective Q4-2025, with Redett moving to lead the laggard GPE segment — a notable redeployment of the credit/strategy architect), a new CHRO (2024), and a new General Counsel (Heinzelman, June-2026, after Ferguson’s retirement). This is a deliberate reconstruction of the leadership team; it signals fresh strategy and energy, but also concentrates execution risk and removes institutional memory — a key-person/execution watch item.

Strategic repositioning (Fact / management framing). The two-year scorecard management cites: AUM +25% to ~$475B; FRE +50% to $1.2B; FRE margin +~1,200bp (off a low base); >$2B returned to shareholders; a comp overhaul shifting more carry to employees and more FRE to shareholders; wealth inflows up 10×; capital-markets revenue tripled to ~$240M. The thesis is explicit: lead with FRE, scale Credit / AlpInvest / wealth / insurance, de-emphasize carry-heavy flagship PE.

Headwinds (Facts):

• Soft Q1-2026 — FRE −3.4% YoY, DE −28% YoY (carry timing), against a 2028 target requiring FRE acceleration.
• Flagship PE stall — GPE FEAUM and FRE down three years; CP VIII size undisclosed; CP IX needing a $5B structured anchor.
• Retail-credit redemptions — CTAC saw “elevated redemptions” in Q1-2026 that management expects to persist amid the June-2026 sector wave (though CG’s exposure is below-average).
• Sector de-rating — the stock fell ~22% YTD with the group, driven by private-credit-redemption fears more than company-specific news.
• Known FRE drags — non-repeating AlpInvest catch-up fees and the CP VII fee-rate step-down (flagged by analysts) make the FRE re-acceleration harder.

Verdict: a credible repositioning meeting a hostile tape. The strategic changes strengthen the long-term thesis (de-risking, growth in the right segments); the near-term headwinds (soft quarter, flagship stall, sector fear) weaken sentiment and explain the discount. On balance the changes are constructive but unproven.

9. Risk Analysis

Overall risk verdict. Carlyle’s risks are overwhelmingly to growth and re-rating, not to solvency. The asset-light, low-leverage, diversified-fee model makes a catastrophic loss very unlikely; the realistic bad outcome is a value trap — a cheap stock that stays cheap because the flagship never re-scales and FRE growth disappoints, leaving the multiple permanently depressed. The downside is cushioned by a covered 3.1% yield and buyback, but the discount can persist for years.

10. Valuation Discussion (Embedded Expectations)

Where it trades. At $45.75, market cap is ~$16.5B (≈360M diluted shares). On the metrics that matter:

• P/DE ≈ 10.9× trailing ($4.20 DE/share)
• P/FRE ≈ 13.3× ($1,236M FRE)
• Forward P/DE ≈ 7.6× on the 2028 $6+ DE/share target
• Dividend yield 3.1%, <50% payout of DE
• AZI own-history valuation percentile: 67th composite — P/B at the 44th percentile (cheaper half of its own range), P/E and P/S percentiles elevated but distorted by depressed GAAP/TTM EPS. Read against its own history, the stock is mid-range to slightly-rich on optical metrics, cheap on book — but the cross-sectional comparison is where the discount is stark.

Peer comparison (the core of the valuation case):

Carlyle trades at roughly half the multiple of Blackstone/KKR and ~two-thirds of Apollo. How much discount is deserved? A lower FRE margin, slower flagship growth, lower genuine perpetual mix, and more carry-dependence all justify a discount — perhaps 20–30%. The market is applying ~45–50%. The gap between “deserved” and “applied” is the opportunity, if it exists.

Embedded-expectations analysis (what the price implies). At ~7.6× the 2028 DE target, the market is underwriting that the 2028 plan fails — i.e., that FRE does not re-accelerate, the flagship does not re-scale, and DE stays near today’s ~$4.20 rather than reaching $6+. Put differently: a no-growth Carlyle earning a steady ~$4.20 DE and paying a covered 3.1% dividend is roughly fairly valued at ~11× today. You are paying almost nothing for the turnaround. If management delivers even half the planned FRE growth and the multiple re-rates to a still-discounted 13–14× DE, the stock works toward the high-$50s; if it delivers the full plan and the multiple normalizes, mid-$60s+ is conceivable. The asymmetry is favorable because expectations are so low — but the catalysts (H2-2026 fundraising, FRE re-acceleration) must actually arrive.

Scenario sketch (illustrative, not a target — no price target per firm policy):

• Bear: flagship stalls, FRE flat, multiple ~9× DE → high-$30s, cushioned by yield.
• Base: partial execution, DE ~$4.75–5.25 by 2027–28, ~12× → low-to-mid $50s.
• Bull: 2028 plan met, $6 DE, ~13–14× → high-$50s to high-$60s.

Verdict: cheap on an absolute and relative basis, with a wide margin of safety in the price, offset by genuine quality reasons for some discount. The embedded expectation is failure; the reasonable base case is partial success. That is a favorable setup, not a slam-dunk.

11. Variant Perception

Consensus view. Carlyle is the perennial also-ran of the big-four alternative managers — lower margin, slower growth, carry-heavy, a CEO turnaround that has improved the narrative more than the numbers. The market prices it as a structurally inferior franchise that deserves its discount, and the June-2026 private-credit scare reinforced the “avoid the laggard” reflex.

Strongest bull case (variant). The market is over-discounting a business whose earnings quality is improving faster than its reputation. FRE is compounding ~20%, the mix is shifting to recurring fee income (73% of DE), Credit and AlpInvest are genuine top-tier growers, the balance sheet is the cleanest in the peer set (no insurance tail risk), and the dividend is covered with a fresh $2B buyback under it. At ~11× DE you are buying a scaled, de-risking oligopolist for half the price of its peers, with the 2028 plan as a free option. A single proof point — a successful CP IX raise plus visible FRE re-acceleration — could re-rate the multiple meaningfully.

Strongest bear case (variant). The discount is correct and possibly insufficient. The flagship PE engine — still the firm’s identity and highest-fee segment — has been shrinking for three years; CP VIII’s undisclosed size and the need to bribe CP IX with a $5B structured anchor suggest the franchise has lost fundraising power. The ~47% margin is structural, not fixable on a stated timeline. The 2028 FRE target requires acceleration from a decelerating base. And the people who know the business best — the founders and the entire executive bench — are not buying a single share, while one founder sells discretionarily. A cheap stock with a stalling core can stay cheap for a very long time. This is a value trap until proven otherwise.

The 3–5 assumptions that decide it:

1. Does the flagship re-scale? CP IX ≥ CP VII (~$14.8B) → bull; materially smaller → bear.
2. Does FRE re-accelerate toward the $1.9B/2028 path (≥~12–15%/yr)?
3. Does the FRE margin progress beyond the mid-40s?
4. Do retail-credit redemptions stay contained to the small CTAC slice?
5. Does carry realize as CP VII/VIII mature into cash-carry (2027–2028)?

Falsifying evidence: Bull is falsified by a sub-scale CP IX raise or a second soft FRE quarter; bear is falsified by a strong H2-2026 fundraising super-cycle plus visible FRE re-acceleration and (decisively) an insider open-market purchase.

Verdict: The variant perception worth holding is that Carlyle’s discount prices a permanent quality deficit, when the more likely outcome is partial convergence — not to best-in-class, but enough to re-rate a stock priced for failure. Conviction is medium precisely because the bear case is well-supported by the flagship data and the insider behavior.

12. Fact vs. Interpretation

13. Open Questions

1. What is CP VIII’s actual raised/target size vs. CP VII (~$14.8B)? Not disclosed on any 2025–2026 earnings call or in the 10-K. The most important undisclosed number in the franchise.
2. What is the magnitude of CTAC retail-credit redemptions (gate level, NAV impact)? Management admitted “elevated” but gave no figures — requires CTAC interval-fund filings.
3. Is there a numeric FRE-margin target, and a year-by-year FRE cadence to $1.9B? Management deferred all specifics to the Feb-26-2026 shareholder deck (not in transcripts).
4. Reconcile the evergreen-AUM definitions ($32B vs. $19B cited in different quarters).
5. Why has not a single insider bought during a 22% drawdown, when KKR’s leadership invested ~$51M? Is it blackout mechanics, conviction, or signaling caution?
6. When do CP VII/VIII reach cash carry, and how dependent is the 2027–2028 DE bridge on exit-market normalization?
7. What is the genuine retail-NAV share of the $209B credit book (CTAC + BDCs as % of GC)?

14. What Must Be True

Bull case — what must be true:

• The H2-2026 “super-cycle” lands: CP IX raises at least in line with CP VII (~$14.8B), the next AlpInvest secondaries vintage is large, and opportunistic credit scales.
• FRE re-accelerates from the soft Q1-2026 toward a ~12–15%/year path consistent with $1.9B by 2028, with the margin progressing beyond the mid-40s.
• Retail-credit redemptions stay contained to the small CTAC slice; the institutional/CLO/insurance book is unaffected.
• Falsification test: Two consecutive quarters of flat-or-declining FRE in H2-2026, OR a CP IX first close materially below CP VII, falsifies the bull case. Either would confirm the flagship has lost fundraising power and the de-rating is structural.

Bear case — what must be true:

• The flagship PE franchise is in secular decline: CP IX raises materially below CP VII, GPE FEAUM keeps shrinking, and the highest-fee segment becomes a permanent drag.
• The ~47% FRE margin is a structural ceiling, not a way-station; scale never converts to peer-level profitability.
• Carry realizations stay weak, leaving DE stuck near ~$4.20 and the multiple permanently depressed.
• Falsification test: A successful CP IX raise (≥ CP VII) plus two quarters of visible FRE re-acceleration, OR an insider open-market purchase of size, falsifies the bear case. Any one would signal the franchise still has fundraising power and management conviction, undermining the value-trap thesis.

The beauty of this name is that both falsification tests resolve on the same near-term events — H2-2026 fundraising and FRE trajectory. The reader will know within two or three quarters which case is right.

15. Source Appendix

See the Source Appendix (Appendix B below) for the full citation list. Primary sources: Carlyle FY2025 Form 10-K (filed 2026-02-27), Q1-2026 Form 10-Q (filed 2026-05-08), prior-year 10-Ks (FY2021–FY2024), 2026 DEF 14A proxy, the Form 4 insider corpus (2025–2026), and Q1-2026 / Q4-2025 / Q3-2025 earnings-call transcripts. Quantitative data: aggregated financial statements, ratios, enterprise value, and valuation multiples; own-history valuation percentiles; market price/market cap. Peer comparison data drawn from the author’s prior work on APO, BX, KKR, and OWL, which rests on those companies’ public filings.

The analysis above carries no investment recommendation and no price target; the sole exception is the clearly-labeled Claude’s Take block at the top, which is the author’s own subjective view and general information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire

The Carlyle Group Inc. (NASDAQ: CG) — as of 2026-06-13

Answers are labeled Fact / Interpretation / Assumption where it matters. Where a question does not map to an alternative asset manager, the correct sector analog is given.

General

What thoughtful questions have other investors asked about this company? From the 2025–2026 earnings calls, the recurring sell-side concerns are: (1) FRE/base-fee growth softness and deceleration — whether mid-/high-single-digit FRE growth is still achievable after a soft Q1-2026, given the CP VII fee-rate step-down and non-repeating AlpInvest catch-up fees (Davitt/Autonomous, Chubak/Wolfe); (2) realization/carry timing — when CP VII/VIII reach cash carry and how dependent monetizations are on exit/M&A markets (Blostein, Schorr, Worthington); (3) retail-credit risk — CTAC redemptions and AlpInvest day-1 markups (O’Brien, Brown); (4) AlpInvest carry economics — record-low carry comp and vintage concentration; (5) buyback runway (Katz). Interpretation: the dominant worry is whether the FRE re-acceleration the 2028 plan requires is real — which is exactly what the cheap multiple reflects.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: mid-cycle and arguably below trend on the carry component. FRE (the recurring base) is at a record and growing; realized carry/DE is depressed by a soft exit market (Q1-2026 realized performance revenues $61.8M vs. $355.1M a year earlier). So distributable earnings are cyclically low on the performance side, high on the fee side.

Driven by the external environment or internal actions? Both. FRE growth is internally driven (fundraising, mix-shift to Credit/Solutions); the DE weakness is externally driven (exit/realization markets, rates). Fact: Q1-2026 DE −28% YoY was almost entirely carry timing, not fee deterioration.

How stable are revenues? Increasingly stable. Fact: FRE is 73% of DE (up from ~60% in 2023); management fees recur on locked, multi-year capital. Carry remains lumpy but is a shrinking share.

Outlook for products/services / how big is the market? Growing. Private-credit TAM ~$1.7T → ~$2.6T (2029); rising institutional alts allocations; 401(k)/wealth penetration (2025 executive order); insurance migration to private credit. Global, multi-asset. Interpretation: the addressable market is expanding faster than Carlyle’s flagship PE franchise is.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: less competitive at the top (consolidating, K-shaped, high barriers), more competitive in commoditizing private-credit lending (spread compression, record dry powder, rising defaults — Fitch ~6.0%, Apr-2026).

How profitable is the business (ROIC, ROE)? Very profitable on a fee-economics basis, but the relevant metric is FRE margin (~47%) and FRE-related return on tangible equity (high — the franchise earns far above cost of capital on its fee streams). GAAP ROE is noisy (~9–49% swings). Fact: the ~47% FRE margin is 10–22 points below peers (BX/APO ~57%, KKR ~69%) — the franchise’s defining profitability weakness.

How profitable is the industry — competitors, barriers? Among the most profitable in financial services for scaled incumbents; barriers (track record, LP trust, scale) are very high. ~6–7 dominant global players.

Can the business be easily understood? Moderately. The fee/carry model is simple; the GAAP-to-DE bridge, fund consolidation, NCI, and tax-receivable agreement are complex. Assumption: a generalist must rely on FRE/DE, not GAAP.

Can it be undermined by foreign low-cost labor? No. It is a relationship-, track-record-, and capital-driven business.

Do brands matter? Yes — “Carlyle” is a 38-year global brand that supports fundraising and deal access. Interpretation: but its brand premium in flagship PE has weakened this cycle (flat GPE FEAUM, undisclosed CP VIII).

Nature of competition / switching costs? Competes on track record, returns, distribution, and product breadth. LP switching costs are high once committed (locked, multi-year capital), but each new fund vintage must be re-won — which is why the flagship-fundraising question is existential.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the net accrued carried interest (“carry bank”) of ~$2.6–2.9B is a real economic asset realized over time, and the brand/track-record/LP-relationship intangibles are unbooked. Tangible book ~$18/share understates franchise value.

Off-balance-sheet liabilities? Limited. GP fund commitments are funded over time; no insurance policyholder liabilities (owns only ~10.5% of Fortitude, indirectly). Fact: this is a clear positive vs. insurance-heavy peers.

How conservative is the accounting? Standard for the sector; non-GAAP FRE/DE are the operative metrics. Interpretation: “perpetual capital” ($115B) overstates genuine sticky retail capital (~$35B ex-Fortitude) — read it skeptically.

How CapEx-hungry is the business? Very capital-light (it’s a fee manager). The “investment” is GP commitments to its own funds, funded from cash flow.

Capital Allocation & Management

How much FCF, and how is it used? DE (~$1.69B FY2025, ~$4.20/share) is the cash-economic profit. Used for: fixed $1.40 dividend (~$505M, <50% payout), buybacks ($400M FY2025 + $205M Q1-2026; ~$1.9B left on a $2B authorization), GP commitments, and bolt-on M&A. Priority: (1) growth, (2) dividend/buyback, (3) inorganic.

Significant acquisitions recently? ~$3B MAI Capital Management (wealth/RIA distribution); $8B BASF coatings carve-out (portfolio deal). Bolt-on/distribution, not transformational. Fact: no insurance acquisition — deliberate asset-light strategy.

Buying back shares? Yes — share count roughly flat (buybacks offset SBC), fresh $2B authorization. Interpretation: management calls the stock cheap to justify it, but see the insider tell below.

Issuing large amounts of stock to insiders? SBC is offset by buybacks; the notable item is the CEO’s 2023 $180M sign-on award (granted under the Nasdaq inducement exception). Upper PSU tranches ($58–72) are now underwater.

Compensation policy / incentive metrics? Company-selected performance measure = FRE; long-term equity tied to absolute stock-price hurdles + relative TSR; annual bonus is a discretionary 0–200% scorecard (Schwartz scored 200% for 2025 despite −22% stock — a say-on-pay sore point, ~82% support). Interpretation: alignment is genuine but the discretionary bonus is a governance blemish.

Motivations of management / insider behavior? Fact (negative tell): zero open-market insider purchases during the 2025–2026 drawdown; founder Rubenstein sold discretionarily (625K @ $56.55 Dec-2025; 500K @ $46.68 Mar-2026). Contrast KKR’s ~$51M of co-CEO/director buying. Founders still own ~24% combined.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — Carlyle converted to a C-corporation (Form 1099, not K-1) years ago; it is a U.S. corporation on Nasdaq. No ADR.

Dividend policy? Fixed $1.40/share annually ($0.35/quarter) — a fixed policy (not the old variable-payout model). Yields ~3.1%, covered at <50% of DE.

How profitable is the business? See above — high fee-economics returns, but the lowest FRE margin (~47%) in the big-four peer set.

Is net income diverging from cash from operations? GAAP net income is essentially uninformative (consolidation/mark-to-market noise); DE is the cash-economic measure and is the right lens. Fact: GAAP and DE diverge structurally — use DE.

Risks & Downside

What would cause the stock to decline? A sub-scale CP IX raise; a second soft FRE quarter; broadening retail-credit redemptions; a private-credit default cycle; a carry-realization drought; loss of confidence in the 2028 plan.

Risk of catastrophic loss? Interpretation: low. Asset-light, low leverage (~$2.7B debt), no insurance liabilities, diversified fee base. The realistic bad outcome is a value trap (cheap stays cheap), not insolvency.

Chance of total loss? Interpretation: very low. A scaled, profitable, low-leverage fee manager with a covered dividend has minimal ruin risk.

Recent News & Events

Has the business environment changed recently? Yes — the June-2026 sector-wide retail private-credit redemption wave de-rated the group and pulled CG down ~22% YTD, despite CG’s below-average retail-credit exposure. Fact: AZI flagged no company-specific “important” news; the move was sector-driven.

Significant acquisitions / accounting changes / new markets? MAI Capital (wealth distribution); the renaming of GIS to “Carlyle AlpInvest”; the wealth-channel build (10× evergreen inflows); the CFO handoff (Redett → Plouffe, with Redett moving to lead GPE). No accounting-policy changes of note.

Recent management changes? Extensive — new CEO (2023), COO (2024), CFO (Q4-2025), CHRO (2024), GC (2026). Interpretation: a deliberate bench rebuild under Schwartz; fresh strategy but concentrated execution/key-person risk.

APPENDIX B — Source Appendix

The Carlyle Group Inc. (NASDAQ: CG) — Research as of 2026-06-13

Primary sources prioritized over secondary. All figures reconciled to filings where possible; ROIC.ai/AZI/yfinance are third-party aggregators used for convenience and cross-check, never as the authority over a filing.

Primary — SEC filings (EDGAR, CIK 0001527166; corpus mirrored locally to output/CG/sources/)

1. Form 10-K, FY2025 — filed 2026-02-27. Segment AUM/FEAUM/FRE/DE, fee rates, perpetual capital, Fortitude advisory relationship, carry bank, dividend/buyback, debt. Source of record for the operating metrics.
2. Form 10-Q, Q1 2026 — filed 2026-05-08. Q1-2026 AUM/FEAUM, FRE $300.0M, DE $327.0M, realized performance revenues $61.8M, net accrued carry $2,587.8M, buyback activity.
3. Forms 10-K, FY2021–FY2024 — multi-year segment trend (FRE, DE, FEAUM by segment); historical GAAP volatility.
4. DEF 14A (2026 proxy) — CEO Schwartz 2023 $180M sign-on award structure and PSU price hurdles ($42.74–$71.80); FRE as company-selected performance measure; NEO comp; founder ownership (~24% combined); say-on-pay history (68%→81%→~82%).
5. Form 4 insider corpus (2025-01 → 2026-05) — 106 filings / 150 transaction lines; transaction-code tally (A=83, F=28, S=15, J=12, G=6, C=6, P=0); Rubenstein discretionary sales (Dec-2025, Mar-2026); Conway charitable gift (3.0M shares).
6. 8-K corpus (2024–2026) — management changes (COO LoBue 2024, CFO Plouffe Q4-2025, GC Heinzelman June-2026), $800M 5.05% notes due 2035 (Sept-2025), $1.0B revolver refresh (May-2025), $2B buyback authorization.

Primary — Earnings-call transcripts (ROIC.ai)

7. Q1 2026 call (2026-05-07) — CEO Schwartz, CFO Plouffe. 2028 targets ($200B inflows / $1.9B FRE / $6+ DE/share); CP IX “later this year” + $5B structured anchor; CTAC “elevated redemptions” expected to persist; management-fee acceleration guidance; $13B inflows; record $96B dry powder.
8. Q4 2025 call (2026-02-06) — FY2025 results; FRE $1,236.2M; deferral of specifics to Feb-26 shareholder deck.
9. Q3 2025 call (2025-10-31) — two-year scorecard; ~55% of firm FRE from GC+AlpInvest; insurance platform $87B; wealth 10× ramp.

Quantitative aggregators (cross-check, reconciled to filings)

10. Aggregated financial data — income statement, balance sheet, profitability ratios, per-share data, enterprise value, valuation multiples, transcript bodies, company profile.
11. Own-history valuation percentiles — composite 67th, P/E 79th, P/B 44th, P/S 78th (P/E distorted by depressed GAAP/TTM EPS).
12. Market data — price $45.75, market cap ~$16.5B, 52-wk range $41.54–$69.85, dividend yield 3.06%, forward P/E ~8.8×.

Peer comparison (public filings)

13. Public filings and earnings reports of Apollo (APO), Blackstone (BX), KKR, and Blue Owl (OWL) — used for peer FRE-margin, perpetual-mix, multiple, dividend, and verdict comparisons, and for shared industry framing (private-credit capital cycle, June-2026 retail redemption wave, FRE re-rating thesis).

Industry / sector context

14. Fitch U.S. private-credit default rate ~6.0% (record, April 2026) — capital-cycle indicator.
15. 2025 U.S. executive order easing private assets into 401(k)/defined-contribution plans — retail-channel tailwind.

Notes on data quality

• GAAP net income is not used for valuation; FRE and DE (non-GAAP, reconciled in the 10-K) are the operative metrics.
• “Perpetual capital” ($115B) is largely (~$80B) the low-fee Fortitude advisory book; genuine retail/evergreen perpetual capital is ~$35B.
• CP VIII raised/target size is not disclosed in any 2025–2026 filing or transcript reviewed — an open question, not an omission of this appendix.
• Peer multiples are approximate, drawn from public filings of varying dates (June 2026); they are directional comparators, not precise same-day figures.